Akeso Biopharma (Cayman) Inc. announced that it will propose revisions to the 2021 Restricted Stock Unit Plan and Stock Option Plan at the annual shareholders' meeting, and terminate the Restricted Stock Unit Plan prior to the initial public offering. This is to comply with the revised and consultation summary of Chapter 17 of the Listing Rules, which will take effect on January 1, 2023, including changes to the definition of designated participants, adoption of plan quotas, updates to reward grant regulations, etc. The annual shareholders' meeting will review the relevant revisions and vote on the revised plan. Akeso Biopharma will apply to the Listing Committee for approval to list and trade shares that may be issued due to reward allocation and exercise of stock options. The Restricted Stock Unit Plan prior to the initial public offering adopted by the company on August 29, 2019, will be terminated upon approval of the shareholders, and the granted rewards will continue to be valid.

Akeso Biopharma (Cayman) Inc. announced that it will propose revisions to the 2021 Restricted Stock Unit Plan and Stock Option Plan at the annual shareholders' meeting, and terminate the Restricted Stock Unit Plan prior to the initial public offering. This is to comply with the revised and consultation summary of Chapter 17 of the Listing Rules, which will take effect on January 1, 2023, including changes to the definition of designated participants, adoption of plan quotas, updates to reward grant regulations, etc. The annual shareholders' meeting will review the relevant revisions and vote on the revised plan. Akeso Biopharma will apply to the Listing Committee for approval to list and trade shares that may be issued due to reward allocation and exercise of stock options. The Restricted Stock Unit Plan prior to the initial public offering adopted by the company on August 29, 2019, will be terminated upon approval of the shareholders, and the granted rewards will continue to be valid.